Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Summit Technology, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Divestiture of the ophthalmic laser firm's Lens Express mail-order contact lens distribution business unit to Strategic Optical Holdings, Inc. for $31 mil. cash plus a minority equity interest in SOH is outlined in a definitive agreement announced May 4. By divesting the unit, Summit will be better able to increase its focus on increasing its share of the laser vision correction market with its LADARVision system, the company explains. Summit had acquired Lens Express in early 1996 (1"The Gray Sheet" April 21, 1997, I&W-10)

You may also be interested in...

Summit Technology taps former Bausch & Lomb exec Robert Palmisano for CEO role.

SUMMIT TECHNOLOGY CEO IS FORMER BAUSCH & LOMB EXEC ROBERT PALMISANO, the ophthalmic laser company announced April 15. Palmisano was with Bausch & Lomb from 1984 until the end of 1995, serving from 1988 until his departure as president of the firm's eyewear division -- which includes the company's sunglass products. He was named a senior VP at B&L in 1992. Palmisano has been consulting since leaving the company.

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.


'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts